New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

CTC Clinical Trial Consultants AB

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

Cancer researcher: “We can do better and reduce suffering”

Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Scientific Solutions

Galderma

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Mercodia AB

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Moderna fälls efter 20 000-kronorserbjudande till barn

Moderna kritiseras i Storbritannien för ett felaktigt meddelande där barn erbjöds 1 500 pund, motsvarande över 20 000 kronor, för deltagande i en klinisk studie...

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Explore our tailored program for Control 2025

Choose an innovation tour, or join our industry-specific guided tours.

TECHNIA AB

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy

FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...

ProPharma

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.